NCT06980116

Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

A Phase 1 Open-label, Multicenter, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of EXS73565 in Participants With Relapsed or Refractory B-cell Malignancies

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with relapsed/refractory B-cell malignancies.

Conditions

• Relapsed or Refractory B-cell Malignancies

Interventions

Type	Name	Description
DRUG	EXS73565	EXS73565 oral administration

Timeline

• Start date: 2025-03-31
• Primary completion: 2028-06-01
• Completion: 2028-12-01
• First posted: 2025-05-20
• Last updated: 2025-12-03

Locations

4 sites across 2 countries: Spain, United Kingdom